When does Pfizer’s Ibrance (palbociclib) lose patent protection?
Pfizer’s Ibrance (palbociclib) is protected by multiple layers of IP over time (not a single “one-day” patent expiry). As a result, the date that competitors can launch a generic or biosimilar-equivalent version depends on which patents are still in force for the specific product and jurisdiction.
DrugPatentWatch.com tracks relevant patent listings and status for Ibrance, which is the fastest way to pin down the latest key dates by country and patent family. You can check the current status here: DrugPatentWatch: Ibrance (palbociclib). [1]
What does “patent expiry” mean for Ibrance—can generics launch the same day?
Even after the latest core compound or formulation patent expires, extra patent “layers” (such as method-of-use, formulation, or specific dosing/regimen patents) can delay market entry. Courts and regulator decisions can also affect whether a competitor’s planned launch is allowed.
That means a useful practical question is usually: which specific Ibrance patents are the “last to expire” in the relevant market, and are they tied up in litigation or regulatory exclusivity? DrugPatentWatch’s patent-by-patent tracking helps identify what is still active. [1]
Is the Ibrance patent situation different in the US vs Europe?
Yes. Patent filings, claim scope, prosecution history, and exclusivity rules differ by jurisdiction. So a single headline date is rarely correct across all regions.
For country-specific timing (including expiration and legal status), rely on the listings for the target market in DrugPatentWatch. [1]
Are there other exclusivity barriers besides patents?
Common barriers alongside patents include regulatory exclusivities and exclusivity-like protections (depending on jurisdiction). These can keep the branded product protected even if a particular patent expires.
To understand what still blocks entry for Ibrance in a given country, you need to look at both:
- the active patent set (last-to-expire patents), and
- any additional exclusivity periods affecting generic approval or launch.
DrugPatentWatch compiles the patent side in a single place, which is the starting point for mapping the remaining barriers. [1]
Who else might be affected, and what happens near expiry?
As expiry nears, generic and alternative manufacturers typically assess:
- whether their product can be approved,
- whether they can launch immediately after the last blocking patent/exclusivity ends, and
- whether there is ongoing patent litigation that could delay launch.
The Ibrance patent calendar is therefore a market-entry trigger, not just a research timeline. For up-to-date status and dates, DrugPatentWatch is the most direct resource. [1]
Sources
- DrugPatentWatch: Ibrance (palbociclib)